Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Pfizer Inc (PFE) NYSE

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 204,017,920
  • Shares Outstanding, K 6,068,350
  • Annual Sales, $ 52,824 M
  • Annual Income, $ 7,215 M
  • 36-Month Beta 0.94
  • Price/Sales 3.86
  • Price/Book 3.21

Price Performance

See More
Period Period Low Period High Performance
1-Month
30.90 +8.80%
on 01/24/17
33.89 -0.80%
on 02/17/17
+1.56 (+4.87%)
since 01/17/17
3-Month
30.51 +10.19%
on 12/08/16
33.89 -0.80%
on 02/17/17
+1.89 (+5.96%)
since 11/17/16
52-Week
28.74 +16.98%
on 03/17/16
37.39 -10.08%
on 08/01/16
+3.99 (+13.47%)
since 02/17/16

Most Recent Stories

More News
New Data in Crohn's Disease Patients Shows Similar Efficacy and Safety Profiles for INFLECTRA(R) and REMICADE(R)a

Data announced jointly today by Pfizer Inc. (NYSE:PFE) and Celltrion Healthcare, at the 12th Congress of the European Crohn's and Colitis Organisation (ECCO), showed that for patients with...

PFE : 33.62 (unch)
Pfizer's Xeljanz Combo Comparable to AbbVie's Humira

Pfizer, Inc. (PFE) announced top-line results from a head-to-head study comparing its rheumatoid arthritis (RA) drug Xeljanz with AbbVie, Inc.'s (ABBV) Humira.

JNJ : 118.86 (+0.66%)
ABBV : 61.77 (+0.47%)
AMGN : 173.29 (+0.69%)
PFE : 33.62 (unch)
Pfizer Announces Top-Line Results from the Oral Strategy Trial of XELJANZ(R) (tofacitinib citrate) Compared to Humira(R) (adalimumab)

Pfizer Inc. (NYSE:PFE) announced today top-line results from ORAL Strategy, a Phase 3B/4 study of XELJANZ(R) (tofacitinib citrate) 5mg twice daily (BID) in the treatment of moderate to severe...

PFE : 33.62 (unch)
Amgen's Repatha CVOT Results Are Potential Game-Changer for Lipid-Lowering Treatment

In its latest Cardiology Report, BioPharm Insight (BPI) reported that Amgen's Repatha Phase III FOURIER trial will be deemed successful by experts if it shows a 35% reduction in major...

SAN : 5.46 (-1.09%)
MDCO : 53.40 (+1.14%)
MRK : 65.39 (+0.20%)
ALNY : 48.28 (+2.68%)
ROG : 78.80 (-1.67%)
AMGN : 173.29 (+0.69%)
PFE : 33.62 (unch)
LLY : 80.39 (+0.44%)
REGN : 371.18 (-0.49%)
NOVN : 5.64 (-4.57%)
MSB : 15.65 (+0.64%)
CAPR : 3.11 (-1.58%)
Merck (MRK) Halts Late Stage Alzheimer Study; Shares Slip

Merck & Co., Inc. (MRK) announced that it is discontinuing a late-stage study evaluating its pipeline candidate, verubecestat for the treatment of mild-to-moderate Alzheimer's disease due to lack of efficacy....

JNJ : 118.86 (+0.66%)
MRK : 65.39 (+0.20%)
LLY : 80.39 (+0.44%)
PFE : 33.62 (unch)
Lisa Ricciardi to Join Board of Directors

YONKERS, NY--(Marketwired - February 15, 2017) - ContraFect Corporation (NASDAQ: CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening,...

CFRX : 2.15 (+7.50%)
PFE : 33.62 (unch)
CMRX : 5.95 (-0.34%)
The Zacks Analyst Blog Highlights: Boeing, Pfizer, Goldman Sachs, NVIDIA and Twitter

The Zacks Analyst Blog Highlights: Boeing, Pfizer, Goldman Sachs, NVIDIA and Twitter

NVDA : 107.23 (-0.02%)
TWTR : 16.62 (+1.65%)
GS : 250.38 (+0.38%)
PFE : 33.62 (unch)
BA : 172.71 (+1.11%)
Allergan To Acquire ZELTIQ in $2.47 Billion Deal, ZELTIQ Shares Pop 13%

Pharmaceutical giant Allergan (AGN) announced on Monday they will acquire ZELTIQ Aesthetics (ZLTQ) in a $2.47 billion deal.

ZLTQ : 55.67 (-0.04%)
AGN : 247.35 (+0.17%)
PFE : 33.62 (unch)
Q4 Scorecard & Analyst Reports for Pfizer, Boeing & Goldman Sachs

Q4 Scorecard & Analyst Reports for Pfizer, Boeing & Goldman Sachs

NVDA : 107.23 (-0.02%)
USB : 54.88 (-0.24%)
TWTR : 16.62 (+1.65%)
GS : 250.38 (+0.38%)
PFE : 33.62 (unch)
BA : 172.71 (+1.11%)
Drug Stocks Earnings Slated for Feb 14: INCY, PRTA & More

The year 2017 seems to have started on a positive note for investors in the U.S. Approximately 71.6% of the companies (or 358 members) in the S&P 500 Index have reported results so far.

CELG : 121.16 (+2.11%)
JNJ : 118.86 (+0.66%)
LLY : 80.39 (+0.44%)
AXON : 12.14 (+0.41%)
INCY : 120.49 (+0.26%)
PRTA : 55.22 (+2.16%)
GILD : 69.85 (-0.65%)
ACOR : 25.30 (unch)
ABBV : 61.77 (+0.47%)
PFE : 33.62 (unch)
BIIB : 288.94 (-0.41%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More

Business Summary

Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company's diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional...

See More

Support & Resistance

2nd Resistance Point 34.04
1st Resistance Point 33.83
Last Price 33.62
1st Support Level 33.47
2nd Support Level 33.32

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.